Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CERO NYSE:NKGN NASDAQ:ONCT NASDAQ:PLRZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCEROCERo Therapeutics$5.40-1.8%$7.71$4.27▼$895.40$6.63M0.47303,801 shs53,607 shsNKGNNKGen Biotech$0.13-7.0%$0.18$0.10▼$0.96$5.96M1.191.49 million shs130 shsONCTOncternal Therapeutics$0.53$0.53$0.53▼$7.17$1.56M1.1899,758 shsN/APLRZPolyrizon$1.20+22.8%$1.08$0.55▼$1,200.00$5.86MN/A267,446 shs39.82 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCEROCERo Therapeutics-1.82%-8.78%-34.78%-26.13%-97.08%NKGNNKGen Biotech0.00%-7.02%-5.36%-59.85%-83.01%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%-87.33%PLRZPolyrizon+22.76%+17.65%+18.81%+43.71%+119,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCEROCERo Therapeutics$5.40-1.8%$7.71$4.27▼$895.40$6.63M0.47303,801 shs53,607 shsNKGNNKGen Biotech$0.13-7.0%$0.18$0.10▼$0.96$5.96M1.191.49 million shs130 shsONCTOncternal Therapeutics$0.53$0.53$0.53▼$7.17$1.56M1.1899,758 shsN/APLRZPolyrizon$1.20+22.8%$1.08$0.55▼$1,200.00$5.86MN/A267,446 shs39.82 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCEROCERo Therapeutics-1.82%-8.78%-34.78%-26.13%-97.08%NKGNNKGen Biotech0.00%-7.02%-5.36%-59.85%-83.01%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%-87.33%PLRZPolyrizon+22.76%+17.65%+18.81%+43.71%+119,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCEROCERo Therapeutics 3.33Buy$45.00733.33% UpsideNKGNNKGen Biotech 0.00N/AN/AN/AONCTOncternal Therapeutics 0.00N/AN/AN/APLRZPolyrizon 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ONCT, PLRZ, NKGN, and CERO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/5/2025CEROCERo TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.008/4/2025CEROCERo TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.006/23/2025CEROCERo TherapeuticsD Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/23/2025CEROCERo TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$30.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCEROCERo TherapeuticsN/AN/AN/AN/A($41.98) per shareN/ANKGNNKGen BiotechN/AN/AN/AN/A($2.68) per shareN/AONCTOncternal Therapeutics$790K1.97N/AN/A$10.19 per share0.05PLRZPolyrizonN/AN/AN/AN/A$315.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCEROCERo Therapeutics-$8.30MN/A0.00∞N/AN/AN/A-209.40%N/ANKGNNKGen Biotech-$82.94M-$2.45N/A∞N/AN/AN/A-479.36%N/AONCTOncternal Therapeutics-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/APLRZPolyrizon-$1.54MN/A0.00∞N/AN/AN/AN/AN/ALatest ONCT, PLRZ, NKGN, and CERO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/22/2025Q2 2025CEROCERo Therapeutics-$70.2290-$61.71+$8.5190-$61.71N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCEROCERo TherapeuticsN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCEROCERo TherapeuticsN/A0.560.56NKGNNKGen BiotechN/A0.020.02ONCTOncternal TherapeuticsN/A2.392.39PLRZPolyrizonN/A10.1610.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCEROCERo Therapeutics29.64%NKGNNKGen Biotech76.17%ONCTOncternal Therapeutics16.05%PLRZPolyrizonN/AInsider OwnershipCompanyInsider OwnershipCEROCERo Therapeutics12.72%NKGNNKGen Biotech10.36%ONCTOncternal Therapeutics11.20%PLRZPolyrizonN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCEROCERo Therapeutics81.21 million1.05 millionN/ANKGNNKGen BiotechN/A44.95 million40.29 millionNot OptionableONCTOncternal Therapeutics302.96 million2.63 millionNo DataPLRZPolyrizonN/A5.99 millionN/AN/AONCT, PLRZ, NKGN, and CERO HeadlinesRecent News About These CompaniesPolyrizon reports intranasal delivery of PL-14 Allergy Blocker in studySeptember 12 at 11:18 AM | msn.comPolyrizon Ltd. Announces Positive Preclinical Results for PL-14 Allergy Blocker as Potential Treatment for Allergic RhinitisSeptember 12 at 7:30 AM | quiverquant.comQPolyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest StudySeptember 12 at 7:26 AM | globenewswire.comPolyrizon (NASDAQ:PLRZ) versus ALX Oncology (NASDAQ:ALXO) Head-To-Head ContrastSeptember 5, 2025 | americanbankingnews.comPolyrizon Regains Nasdaq ComplianceAugust 14, 2025 | msn.comPolyrizon Ltd. Regains Compliance with Nasdaq Listing RequirementsAugust 14, 2025 | quiverquant.comQPolyrizon Regains Compliance with Nasdaq Listing RequirementsAugust 14, 2025 | globenewswire.comPolyrizon Ltd. Announces Special General Meeting for September 2025July 31, 2025 | tipranks.comPolyrizon stock soars after promising nasal allergy blocker test resultsJuly 23, 2025 | in.investing.comPolyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest StudyJuly 22, 2025 | globenewswire.comPolyrizon Ltd.: Polyrizon Retains Nasdaq Listing Following Hearings PanelJuly 15, 2025 | finanznachrichten.dePolyrizon retains Nasdaq listing following hearings panelJuly 15, 2025 | msn.comPolyrizon Retains Nasdaq Listing Following Hearings PanelJuly 15, 2025 | globenewswire.comPolyrizon’s nasal drug delivery system shows promising resultsJune 14, 2025 | uk.investing.comPolyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its ...June 12, 2025 | bakersfield.comBPolyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS TherapeuticsJune 12, 2025 | globenewswire.comPolyrizon Ltd. Receives Nasdaq Notification of Potential Delisting Due to Shareholder Dilution ConcernsMay 23, 2025 | quiverquant.comQPolyrizon Announces Receipt of Nasdaq Delisting NoticeMay 23, 2025 | globenewswire.comPolyrizon Ltd. Announces Reverse Share Split Effective May 27, 2025May 22, 2025 | tipranks.comPolyrizon Emerges with Positive Preclinical Data on Nasal Protection PlatformMay 21, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeONCT, PLRZ, NKGN, and CERO Company DescriptionsCERo Therapeutics NASDAQ:CERO$5.40 -0.10 (-1.82%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.40 +0.00 (+0.09%) As of 09/12/2025 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.NKGen Biotech NYSE:NKGN$0.13 -0.01 (-7.02%) As of 09/12/2025 09:43 AM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Oncternal Therapeutics NASDAQ:ONCTOncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.Polyrizon NASDAQ:PLRZ$1.20 +0.22 (+22.76%) As of 09/12/2025 04:00 PM EasternPolyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
